HZNP logo

Horizon Therapeutics Public Limited (HZNP) Cash From Operations

Annual CFO

$1.26 B
+$222.57 M+21.50%

31 December 2022

HZNP Cash From Operations Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Quarterly CFO

$161.47 M
+$75.14 M+87.05%

30 June 2023

HZNP Quarterly CFO Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

TTM CFO

$1.04 B
-$87.73 M-7.77%

30 June 2023

HZNP TTM CFO Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

HZNP Cash From Operations Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year---
3 y3 years+126.4%-60.7%+14.8%
5 y5 years+546.6%+84.5%+202.8%

HZNP Cash From Operations High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3 yearsat high+126.4%-70.0%+87.0%-26.4%+14.8%
5 y5 yearsat high+546.6%-70.0%+358.0%-26.4%+238.3%
alltimeall timeat high+1741.2%-70.0%+328.3%-26.4%+1423.6%

Horizon Therapeutics Public Limited Cash From Operations History

DateAnnualQuarterlyTTM
June 2023
-
$161.47 M(+87.0%)
$1.04 B(-7.8%)
Mar 2023
-
$86.32 M(-79.8%)
$1.13 B(-10.3%)
Dec 2022
$1.26 B(+21.5%)
$426.39 M(+16.4%)
$1.26 B(-8.2%)
Sept 2022
-
$366.46 M(+47.1%)
$1.37 B(-3.2%)
June 2022
-
$249.20 M(+15.5%)
$1.41 B(+12.7%)
Mar 2022
-
$215.79 M(-59.9%)
$1.25 B(+21.2%)
Dec 2021
$1.04 B(+86.3%)
$538.56 M(+31.0%)
$1.04 B(+14.2%)
Sept 2021
-
$411.04 M(+359.8%)
$906.53 M(+50.0%)
June 2021
-
$89.40 M(-2498.1%)
$604.35 M(-1.7%)
Mar 2021
-
-$3.73 M(-100.9%)
$614.55 M(+10.6%)
Dec 2020
$555.69 M(+30.3%)
$409.82 M(+276.5%)
$555.69 M(+64.8%)
Sept 2020
-
$108.86 M(+9.3%)
$337.25 M(+6.8%)
June 2020
-
$99.60 M(-259.1%)
$315.90 M(+2.7%)
Mar 2020
-
-$62.59 M(-132.7%)
$307.57 M(-27.9%)
Dec 2019
$426.33 M(+119.1%)
$191.38 M(+118.7%)
$426.33 M(+24.1%)
Sept 2019
-
$87.52 M(-4.1%)
$343.66 M(+0.8%)
June 2019
-
$91.27 M(+62.5%)
$341.00 M(+9.5%)
Mar 2019
-
$56.17 M(-48.3%)
$311.52 M(+60.1%)
Dec 2018
$194.54 M(-31.6%)
$108.71 M(+28.1%)
$194.54 M(-15.1%)
Sept 2018
-
$84.86 M(+37.3%)
$229.09 M(+7.8%)
June 2018
-
$61.78 M(-201.6%)
$212.58 M(+7.0%)
Mar 2018
-
-$60.81 M(-142.4%)
$198.72 M(-30.1%)
Dec 2017
$284.34 M(-23.0%)
$143.26 M(+109.6%)
$284.34 M(+1.5%)
Sept 2017
-
$68.35 M(+42.6%)
$280.26 M(-17.7%)
June 2017
-
$47.92 M(+93.2%)
$340.70 M(+0.2%)
Mar 2017
-
$24.81 M(-82.2%)
$340.08 M(-8.0%)
Dec 2016
$369.46 M
$139.19 M(+8.1%)
$369.46 M(+1.2%)
Sept 2016
-
$128.79 M(+172.3%)
$365.21 M(+12.4%)
June 2016
-
$47.30 M(-12.7%)
$324.81 M(+1.8%)
DateAnnualQuarterlyTTM
Mar 2016
-
$54.18 M(-59.8%)
$319.09 M(+64.3%)
Dec 2015
$194.17 M(+604.8%)
$134.94 M(+52.7%)
$194.17 M(+180.2%)
Sept 2015
-
$88.38 M(+112.5%)
$69.31 M(-493.6%)
June 2015
-
$41.58 M(-158.8%)
-$17.61 M(-58.5%)
Mar 2015
-
-$70.74 M(-801.8%)
-$42.43 M(-254.0%)
Dec 2014
$27.55 M(-150.7%)
$10.08 M(+587.5%)
$27.55 M(+337.8%)
Sept 2014
-
$1.47 M(-91.3%)
$6.29 M(-236.3%)
June 2014
-
$16.76 M(-2314.1%)
-$4.62 M(-85.7%)
Mar 2014
-
-$757.00 K(-93.2%)
-$32.27 M(-40.5%)
Dec 2013
-$54.29 M(-29.2%)
-$11.18 M(+18.4%)
-$54.29 M(-9.9%)
Sept 2013
-
-$9.44 M(-13.4%)
-$60.28 M(-18.2%)
June 2013
-
-$10.90 M(-52.1%)
-$73.66 M(-6.3%)
Mar 2013
-
-$22.77 M(+32.6%)
-$78.62 M(+2.6%)
Dec 2012
-$76.64 M(+84.5%)
-$17.17 M(-24.8%)
-$76.64 M(+3.5%)
Sept 2012
-
-$22.83 M(+43.9%)
-$74.07 M(+9.7%)
June 2012
-
-$15.86 M(-23.7%)
-$67.54 M(+21.0%)
Mar 2012
-
-$20.79 M(+42.4%)
-$55.83 M(+34.4%)
Dec 2011
-$41.54 M(+10.7%)
-$14.60 M(-10.4%)
-$41.54 M(+18.5%)
Sept 2011
-
-$16.29 M(+292.8%)
-$35.07 M(+16.1%)
June 2011
-
-$4.15 M(-36.2%)
-$30.21 M(-23.1%)
Mar 2011
-
-$6.50 M(-20.1%)
-$39.26 M(+4.6%)
Dec 2010
-$37.53 M(+104.1%)
-$8.13 M(-28.9%)
-$37.53 M(+11.3%)
Sept 2010
-
-$11.43 M(-13.4%)
-$33.73 M(+26.7%)
June 2010
-
-$13.20 M(+176.7%)
-$26.63 M(+48.1%)
Mar 2010
-
-$4.77 M(+10.3%)
-$17.98 M(-2.2%)
Dec 2009
-$18.39 M(-23.3%)
-$4.32 M(-0.3%)
-$18.39 M(+30.7%)
Sept 2009
-
-$4.33 M(-4.8%)
-$14.07 M(+44.5%)
June 2009
-
-$4.55 M(-12.0%)
-$9.73 M(+88.0%)
Mar 2009
-
-$5.18 M
-$5.18 M
Dec 2008
-$23.97 M
-
-

FAQ

  • What is Horizon Therapeutics Public Limited annual cash flow from operations?
  • What is the all time high annual CFO for Horizon Therapeutics Public Limited?
  • What is Horizon Therapeutics Public Limited quarterly cash flow from operations?
  • What is the all time high quarterly CFO for Horizon Therapeutics Public Limited?
  • What is Horizon Therapeutics Public Limited TTM cash flow from operations?
  • What is the all time high TTM CFO for Horizon Therapeutics Public Limited?

What is Horizon Therapeutics Public Limited annual cash flow from operations?

The current annual CFO of HZNP is $1.26 B

What is the all time high annual CFO for Horizon Therapeutics Public Limited?

Horizon Therapeutics Public Limited all-time high annual cash flow from operations is $1.26 B

What is Horizon Therapeutics Public Limited quarterly cash flow from operations?

The current quarterly CFO of HZNP is $161.47 M

What is the all time high quarterly CFO for Horizon Therapeutics Public Limited?

Horizon Therapeutics Public Limited all-time high quarterly cash flow from operations is $538.56 M

What is Horizon Therapeutics Public Limited TTM cash flow from operations?

The current TTM CFO of HZNP is $1.04 B

What is the all time high TTM CFO for Horizon Therapeutics Public Limited?

Horizon Therapeutics Public Limited all-time high TTM cash flow from operations is $1.41 B